SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Smol Fans

SMOL, a rescue dog turned meme coin, is trending due to its unique story and organic community growth, distinguishing it from typical Solana plays. Community members highlight its potential for cross-platform appeal and long-term viability, drawing comparisons to DOGE and emphasizing the project's strong foundation. The project's association with OnlyFans and dog rescue efforts is a key talking point.

Fly-E Group, Inc. is an electric vehicle company, which engages in designing, installing, and selling smart electric motorcycles, electric bikes, electric scooters, and related accessories under the brand Fly E-Bike. Its products include electric-scooter, e-bikes, parts, and accessories. The company was founded by Zhou Ou in 2018 and is headquartered in Flushing, NY.

Fly-E Group Inc.

Fly-E Group Inc

The stock is trending due to a massive price swing, with community members pointing to potential manipulation and a short squeeze, while others cite negative reports. Discussions revolve around the relationship between FLYE and its 'sister stock' FLYX. Overall sentiment is mixed, with bag holders hoping for a rebound and short sellers expecting further declines.

Ambitions Enterprise Management Co LLC

AHMA is trending due to a surge in price and trading volume, leading to multiple trading halts, with chatter focusing on a potential short squeeze and comparisons to other recent high-flying IPOs like $SMX. The community is actively discussing price targets ranging from $20 to $50, driven by the stock's low float and recent IPO status, with some traders drawing parallels to other low-float stocks that have experienced significant gains.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy stock is trending amid discussions about its correlation to Bitcoin's price movements, with community members debating its financial strategy and potential risks associated with its debt and Bitcoin holdings. Bullish and bearish sentiments are clashing, with some seeing it as oversold and others as a potential "Ponzi scheme" due to its business model and recent stock dilutions. The debate includes speculation on potential institutional moves and the impact of Bitcoin's price on the company's future.

Coincheck Group NV operates multi-cryptocurrency marketplaces and crypto asset exchanges in Japan. It provides exchange platforms on cryptocurrencies including Bitcoin and Ethereum. It owns the Next Finance Tech Company Limited that offers staking services to retail customers and corporate clients. The company was founded on February 18, 2022 and is headquartered in Amsterdam, Netherland.

Coincheck Group N.V.

CNCK (Coincheck Group N.V.) is experiencing significant volatility and trending upwards, with some traders eyeing a potential breakout. The stock's surge is attributed to its undervalued status, acquisition news, and association with the crypto sector, although the specific catalyst remains unclear to some. Community members are actively discussing key price levels and potential shorting opportunities, while also noting potential risks.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is trending as analysts highlight its role in Google's AI initiatives, particularly the increasing demand and pricing for Broadcom's Tensor Processing Units (TPUs) used in Google's AI infrastructure. Community members are discussing potential price target increases and the impact of Meta potentially using Google's TPUs, framing it as a competition dynamic with Nvidia in the AI chip space. Bullish sentiment suggests further upside potential, while some caution against the rapid price increase and potential for a pullback.

Gitlab, Inc. provides code hosting and collaboration platform services. It offers continuous integration, source code management, out-of-the-box pipelines, agile development, and value stream management. The company was founded by Dmitriy Zaporozhets and Sid Sijbrandij in 2011 and is headquartered in Dover, DE.

Gitlab Inc - Ordinary Shares - Class A

Gitlab Inc

GitLab is trending amid both positive catalysts and community concerns, including a recent analyst upgrade countered by a downgrade, and chatter around a potential acquisition. The community is weighing the potential impact of AI on GitLab's business model, while also assessing its competitive position against GitHub and other startups. Discussions also involve large short positions and potential earnings catalysts.

Accenture is a global professional services company that helps the world’s businesses, governments and other organizations build their digital core, optimize their operations, accelerate revenue growth and enhance citizen services, creating tangible value at speed and scale. The firm combines technology and leadership in cloud, data and AI with industry experience, functional expertise and global delivery capability. Its services include Strategy & Consulting, Technology, Operations, Industry X, and Song. It operates through the following geographical segments: North America, EMEA, and Growth Markets. The company was founded in 1951 and is headquartered in Dublin, Ireland.

Accenture plc - Ordinary Shares - Class A

Accenture ($ACN) is trending amid discussions of its partnership with OpenAI to integrate ChatGPT Enterprise, sparking investor interest and a nearly 5% surge in the stock. Community members are analyzing the potential benefits for both companies, especially how this deal could position Accenture as a key player in enterprise AI adoption, despite the company's year-to-date underperformance. Investors are seeing this as a possible turning point, supported by solid fundamentals and a fresh AI-driven catalyst.

Spruce Biosciences, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

Spruce Biosciences Inc

SPRB is experiencing significant volatility as investors discuss the implications of a recent financing announcement and its potential dilution. The community is weighing whether the stock is currently oversold, while also comparing it to other high-flying biotech stocks with low floats. Some traders are closely watching key price levels and potential short squeeze opportunities.

This is directly from our website -   DELULU isn’t just a coin - it’s a movement. A tokenized culture of belief, confidence, and freedom. We stand against the ordinary life that society expects us to live. We are the ones bold enough to dream, to take action, and to create our own future. This is more than crypto - it’s a mentality. Delusion is power. It’s believing in your vision long before anyone else does. But DELULU is also a community - a network of dreamers and believers united by one idea: that the impossible becomes possible when enough of us refuse to doubt ourselves. It’s tokenized belief. Every holder is a part of the story - a living symbol of confidence, persistence, and freedom. Together, we turn delusion into reality.

Delusional Coin

Delusional Coin ($DELULU) is trending as the community rallies around its concept, which centers on the idea that collective belief in the coin's potential can drive its success. Social media posts indicate the coin is built on Solana ($SOL) and draws comparison to Bonk ($BONK), fueling community discussion and speculative interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives Consensus Recommendation of "Hold" from Brokerages

Shares of Spruce Biosciences, Inc. (NASDAQ:SPRB - Get Free Report) have been assigned a consensus rating of "Hold" from the ten ratings firms that are covering the firm, Marketbeat.com reports. One...

Citizens Jmp Forecasts Strong Price Appreciation for Spruce Biosciences (NASDAQ:SPRB) Stock

Citizens Jmp raised their price target on Spruce Biosciences from $254.00 to $259.00 and gave the stock a "market outperform" rating in a research report on Tuesday...

Spruce Biosciences (NASDAQ:SPRB) Releases Quarterly Earnings Results, Beats Estimates By $0.98 EPS

Spruce Biosciences (NASDAQ:SPRB - Get Free Report) released its quarterly earnings data on Monday. The company reported ($14.58) earnings per share (EPS) for the quarter, beating analysts' consensus...

Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical...

What Makes Spruce Biosciences, Inc. (SPRB) a Strong Momentum Stock: Buy Now?

Does Spruce Biosciences, Inc. (SPRB) have what it takes to be a top stock pick for momentum investors? Let's find out.

Shares of Spruce Biosciences (SPRB) surged to a 19-month high of $240 in Tuesday morning trading, prompting two trading halts due to extreme volatility.Trading was halted at 9:32 a.m. ET and again at 9:48 a.m. ET, according to data from Nasdaq Trader, citing a ‘Volatility Trading Pause’.<a href="http://stocktwits.com/symbol/SPRB">SPRB’s stock</a> was up 74%, trading around $229 at the time of writing. It ranked among the top trending tickers on Stocktwits, with retail sentiment climbing higher within ‘extremely bullish’ territory amid ‘extremely high’ chatter – recording the highest levels of retail activity seen this year. Data also showed that the number of retail traders monitoring SPRB shares jumped 76% over the past day.<figure class="image"><img style="aspect-ratio:1259/133;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_07_101031_png_dc3a1a3a6c.webp" alt="Screenshot 2025-10-07 101031.png" width="1259" height="133"><figcaption>SPRB retail sentiment and message volume on October 7 as of 10:00 a.m. ET | Source: Stocktwits</figcaption></figure>The rally follows Spruce Biosciences’ shares jumping 1,378% to close at $130.4 on Monday after the U.S. Food and Drug Administration (FDA)&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spruce-biosciences-stock-more-than-quadruples-after-breakthrough-therapy-designation-to-therapy-for-rare-fatal-genetic-disease/ch6R7WfR3gl">granted</a> Breakthrough Therapy Designation to tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB).Martin Shkreli also&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spruce-biosciences-stock-nearly-doubles-premarket-pharma-bro-martin-shkreli-sees-280-upside/ch6PEVhR3Wj">disclosed</a> his long position in Spruce and expressed a bullish outlook. In a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/MartinShkreli/status/1975241784369262649">post</a> on X, Shkreli said he believes the treatment “will be approved” and become “the new standard of care,” predicting that Spruce’s stock could rise to $500. Shkreli, a former hedge fund manager and pharmaceutical executive who&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.justice.gov/usao-edny/pr/martin-shkreli-sentenced-seven-years-imprisonment-multi-million-dollar-fraud-scheme">served time</a> for securities fraud, did not provide a timeline for the forecast.MPS IIIB is a rare, inherited lysosomal storage disease that causes a gradual decline in motor skills and cognition, as well as hyperactivity with aggressive behavior. CEO Javier Szwarcberg said on Monday that the company is preparing to submit an application for approval of the therapy in MPS IIIB in the first quarter of 2026.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bnb-token-surges-to-record-high-overtakes-xrp-as-third-largest-cryptocurrency/ch6PaXTR3Wy">BNB Token Surges To Record High, Overtakes XRP As Third-Largest Cryptocurrency</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of abstract numbers amid rising stock market prices. (Photo by SEAN GLADWELL/Getty Images)

SPRB Stock Hits 19-Month High Amid Trading Halts

The rally follows Spruce Biosciences’ shares jumping 1,378% to close at $130.4 on Monday.

Equity

The rally follows Spruce Biosciences’ shares jumping 1,378% to close at $130.4 on Monday.


Spruce Biosciences' stock&nbsp;leaped over 90% in early premarket trading on Tuesday, topping the Stocktwits trending list,&nbsp;hours after investor Martin Shkreli disclosed his long position on the stock and discussed his optimistic outlook.That's after SPRB stock gained a staggering 1,378% to $130.4 in Monday's session, following the company's announcement that it&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/spruce-biosciences-stock-more-than-quadruples-after-breakthrough-therapy-designation-to-therapy-for-rare-fatal-genetic-disease/ch6R7WfR3gl">received</a> the FDA's 'Breakthrough Therapy Designation' for its new therapy for a rare neurological disease.Spruce's tralesinidase alfa enzyme replacement therapy (TA-ERT) is designed to treat Sanfilippo syndrome type B (MPS IIIB), a rare, inherited lysosomal storage disease that causes a gradual decline in motor skills and cognition, as well as hyperactivity with aggressive behavior.Shkreli said in an&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/MartinShkreli/status/1975241784369262649">X post</a> early Tuesday he believes the said treatment "will be approved" and become "the new standard of care," forecasting that it would push Spruce's stock to $500.&nbsp;Shkreli, a former hedge fund manager and pharmaceutical executive who has served time in jail for securities fraud, did not provide a timeline."I was working on a presentation when the news was scooped. but this drug restores the abnormally high levels of heparan sulfate to normal. without this drug, patients will die at 18. with normal ranges of HS, they may live a normal life," he said in a follow-up post.CEO Javier Szwarcberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251006024469/en/Spruce-Biosciences-Receives-U.S.-FDA-Breakthrough-Therapy-Designation-for-Tralesinidase-Alfa-Enzyme-Replacement-Therapy-TA-ERT-in-Sanfilippo-Syndrome-Type-B-MPS-IIIB">said</a> on Monday that the company is preparing to submit an application for approval of the therapy in MPS IIIB in the first quarter of 2026. According to Spruce, Sanfilippo Syndrome Type B affects one in 200,000 people in the U.S.FDA's 'Breakthrough Therapy Designation' expedites the development and regulatory review of promising therapies for serious or life-threatening conditions, with intensive FDA guidance.Notably, Shkreli also recently&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pharma-bro-martin-shkreli-bets-against-opendoor-but-retail-traders-call-it-an-obvious-long-backed-by-eric-jackson/chw0M0bRdsE">revealed a short position</a> in Opendoor Technologies' shares, a widely watched meme stock.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Spruce Biosciences Stock Nearly Doubles Premarket: 'Pharma Bro' Martin Shkreli Sees 280% Upside

SPRB stock surged by over 1,300% on Monday after the biotech firm received the FDA's 'Breakthrough Therapy Designation' for its new therapy for a rare neurological disease.

Spruce Biosciences (SPRB) on Monday said that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B.Sanfilippo syndrome type B (MPS IIIB) is a rare, inherited lysosomal storage disease caused by a deficiency in the enzyme alpha-N-acetylglucosaminidase, leading to the accumulation of heparan sulfate in cells, particularly neurons. It causes progressive neurological symptoms like cognitive and developmental impairment, hyperactivity with aggressive and destructive behavior, delayed speech, hearing loss, and motor skill deficits.Tralesinidase Alfa Enzyme Replacement Therapy is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB. The Breakthrough Therapy Designation is designed to expedite the development and regulatory review of promising therapies for serious or life-threatening conditions. It enables intensive FDA guidance and eligibility for rolling submission and priority review.Shares of SPRB traded 314% higher at the time of writing on Monday. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SPRB">SPRB stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume stayed at ‘extremely high’ levels.CEO Javier Szwarcberg <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20251006024469/en/Spruce-Biosciences-Receives-U.S.-FDA-Breakthrough-Therapy-Designation-for-Tralesinidase-Alfa-Enzyme-Replacement-Therapy-TA-ERT-in-Sanfilippo-Syndrome-Type-B-MPS-IIIB">said</a> that the company is preparing to submit an application for approval of the therapy in MPS IIIB in the first quarter of 2026. According to Spruce, Sanfilippo Syndrome Type B affects one in 200,000 people in the U.S.Currently, there are no FDA-approved therapies for the disease, which drastically brings down the life expectancy of individuals to 15-19 years of age.SPRB stock rose over 200% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-listed-nyxoah-shares-soar-on-first-genio-system-implants-in-patients-with-sleep-disorder/ch6R4LYR3g1">US-Listed Nyxoah Shares Soar On First Genio System Implants In Patients With Sleep Disorder</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did Spruce Biosciences Stock Quadruple Today?

The FDA’s Breakthrough Therapy Designation is designed to expedite the development and regulatory review of promising therapies for serious or life-threatening conditions.

Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates

Puma Biotech (PBYI) delivered earnings and revenue surprises of +36.36% and +4.42%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Curis (CRIS) Reports Q2 Loss, Beats Revenue Estimates

Curis (CRIS) delivered earnings and revenue surprises of +65.83% and +14.54%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

$CRWD

$CRM

$SNOW

$MDB

Which earnings report are you most looking forward to this week? 
 
Drop a comment for others.

Current Price	$79.01
Prev Close	$100.00
Open	$102.10
Dividend Yield	0.00%
50-Day Moving Average	$101.60
Beta	1.18
Avg. Volume	1.35M
PE Ratio	-1.18

52-Week High	$240.00
52-Week Low	$4.28
Market Capitalization	$107.04M
EPS (Annual)	-$96.39
Price to Book	10.46
Revenue Per Employee	$233,857.14
Enterprise Value/EBITDA	N/A

SPRB
Spruce Biosciences Inc

Feed

News

Sentiment

Fundamentals

Info

Latest SPRB News

SPRBSpruce Biosciences Inc